Rogier C. Buijsman

1.7k total citations
49 papers, 1.3k citations indexed

About

Rogier C. Buijsman is a scholar working on Molecular Biology, Cell Biology and Organic Chemistry. According to data from OpenAlex, Rogier C. Buijsman has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 14 papers in Cell Biology and 10 papers in Organic Chemistry. Recurrent topics in Rogier C. Buijsman's work include Microtubule and mitosis dynamics (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Melanoma and MAPK Pathways (5 papers). Rogier C. Buijsman is often cited by papers focused on Microtubule and mitosis dynamics (11 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Melanoma and MAPK Pathways (5 papers). Rogier C. Buijsman collaborates with scholars based in Netherlands, Germany and United Kingdom. Rogier C. Buijsman's co-authors include Guido J.R. Zaman, Joost C.M. Uitdehaag, Jos de Man, Martine B.W. Prinsen, Nicole Willemsen‐Seegers, C. A. A. VAN BOECKEL, Antoon M. van Doornmalen, Martin de Kort, Jeroen A.D.M. de Roos and Jules P.P. Meijerink and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Angewandte Chemie International Edition and Journal of Clinical Oncology.

In The Last Decade

Rogier C. Buijsman

48 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rogier C. Buijsman Netherlands 20 566 249 230 173 152 49 1.3k
Gary E. Schiltz United States 18 910 1.6× 265 1.1× 306 1.3× 67 0.4× 72 0.5× 52 1.5k
Jen‐Shin Song Taiwan 22 625 1.1× 346 1.4× 273 1.2× 82 0.5× 37 0.2× 58 1.4k
Yasuhiro Maeda Japan 23 968 1.7× 108 0.4× 101 0.4× 93 0.5× 213 1.4× 74 1.6k
Yasuhiro Hashimoto Japan 22 722 1.3× 167 0.7× 168 0.7× 120 0.7× 74 0.5× 59 1.6k
Biyin Cao China 27 1.2k 2.1× 114 0.5× 392 1.7× 84 0.5× 291 1.9× 59 1.6k
Tatiana Koudriakova United States 17 596 1.1× 134 0.5× 429 1.9× 34 0.2× 33 0.2× 26 1.4k
Anthony E. Boitano United States 15 1.1k 2.0× 93 0.4× 374 1.6× 171 1.0× 762 5.0× 61 2.3k
David Meininger United States 19 689 1.2× 41 0.2× 124 0.5× 115 0.7× 93 0.6× 22 1.2k
Manuel Melo Pires Portugal 25 956 1.7× 130 0.5× 100 0.4× 110 0.6× 122 0.8× 86 2.0k
Kimiko Ishiguro United States 25 822 1.5× 190 0.8× 145 0.6× 152 0.9× 71 0.5× 71 1.5k

Countries citing papers authored by Rogier C. Buijsman

Since Specialization
Citations

This map shows the geographic impact of Rogier C. Buijsman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rogier C. Buijsman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rogier C. Buijsman more than expected).

Fields of papers citing papers by Rogier C. Buijsman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rogier C. Buijsman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rogier C. Buijsman. The network helps show where Rogier C. Buijsman may publish in the future.

Co-authorship network of co-authors of Rogier C. Buijsman

This figure shows the co-authorship network connecting the top 25 collaborators of Rogier C. Buijsman. A scholar is included among the top collaborators of Rogier C. Buijsman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rogier C. Buijsman. Rogier C. Buijsman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Forster, Nicole, Felix Bachmann, Paul M.J. McSheehy, et al.. (2024). Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination. Frontiers in Oncology. 14. 1447807–1447807. 1 indexed citations
2.
Uitdehaag, Joost C.M., et al.. (2024). 183 (PB171): A novel kinase degrader-based payload for the development of potent Degrader Antibody Conjugates (DACs). European Journal of Cancer. 211. 114704–114704. 1 indexed citations
3.
Giczewska, Anna, Aslι Küçükosmanoğlu, Rogier C. Buijsman, et al.. (2023). Screening of predicted synergistic multi-target therapies in glioblastoma identifies new treatment strategies. Neuro-Oncology Advances. 5(1). vdad073–vdad073. 8 indexed citations
4.
Perez‐Pardo, Paula, Nicole Willemsen‐Seegers, Youri Adolfs, et al.. (2021). Pharmacological validation of TDO as a target for Parkinson’s disease. FEBS Journal. 288(14). 4311–4331. 19 indexed citations
5.
Clemente, Gonçalo S., Inês F. Antunes, Jürgen W. A. Sijbesma, et al.. (2021). Mapping Arginase Expression with 18F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids. Journal of Nuclear Medicine. 62(8). 1163–1170. 4 indexed citations
6.
Zaman, Guido J.R., Antoon M. van Doornmalen, Wilhelmina E. van Riel, et al.. (2020). Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites. Oncotarget. 11(49). 4570–4581. 8 indexed citations
7.
Willemsen‐Seegers, Nicole, Joost C.M. Uitdehaag, Jos de Man, et al.. (2020). High-Throughput Fluorescence-Based Activity Assay for Arginase-1. SLAS DISCOVERY. 25(9). 1018–1025. 7 indexed citations
8.
Uitdehaag, Joost C.M., et al.. (2019). Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. SHILAP Revista de lepidopterología. 4. 100014–100014. 34 indexed citations
9.
Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Martine B.W. Prinsen, et al.. (2018). Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017. Molecular Cancer Therapeutics. 18(2). 470–481. 20 indexed citations
10.
Zaman, Guido J.R., Jeroen A.D.M. de Roos, Martine B.W. Prinsen, et al.. (2017). TTK Inhibitors as a Targeted Therapy for CTNNB1 ( β -catenin) Mutant Cancers. Molecular Cancer Therapeutics. 16(11). 2609–2617. 40 indexed citations
11.
Uitdehaag, Joost C.M., Jos de Man, Nicole Willemsen‐Seegers, et al.. (2017). Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. Journal of Molecular Biology. 429(14). 2211–2230. 44 indexed citations
12.
Uitdehaag, Joost C.M., Jeroen A.D.M. de Roos, Martine B.W. Prinsen, et al.. (2016). Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors. Molecular Cancer Therapeutics. 15(12). 3097–3109. 12 indexed citations
13.
Canté-Barrett, Kirsten, J A P Spijkers-Hagelstein, Jessica G. C. A. M. Buijs-Gladdines, et al.. (2016). MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia. Leukemia. 30(9). 1832–1843. 79 indexed citations
14.
Willemsen‐Seegers, Nicole, Joost C.M. Uitdehaag, Martine B.W. Prinsen, et al.. (2016). Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. Journal of Molecular Biology. 429(4). 574–586. 37 indexed citations
15.
Maia, Ana, Ute Boon, Aniek Janssen, et al.. (2015). Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Annals of Oncology. 26(10). 2180–2192. 93 indexed citations
16.
Uitdehaag, Joost C.M., et al.. (2012). A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. British Journal of Pharmacology. 166(3). 858–876. 80 indexed citations
17.
Buijsman, Rogier C., et al.. (2005). Non-Steroidal Steroid Receptor Modulators. Current Medicinal Chemistry. 12(9). 1017–1075. 38 indexed citations
18.
Vogel, G.M.T., et al.. (2003). Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity. Journal of Thrombosis and Haemostasis. 1(9). 1945–1954. 15 indexed citations
19.
Buijsman, Rogier C., et al.. (1999). Synthesis of heparin-like antithrombotics having perphosphorylated thrombin binding domains. Bioorganic & Medicinal Chemistry. 7(9). 1881–1890. 15 indexed citations
20.
Buijsman, Rogier C., Will H. A. Kuijpers, Jan E. M. Basten, et al.. (1996). Synthesis of a Pentasaccharide–Oligonucleotide Conjugate: A Novel Antithrombotic Agent. Chemistry - A European Journal. 2(12). 1572–1577. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gary E. Schiltz Breakdown of academic impact, for papers by Jen‐Shin Song Breakdown of academic impact, for papers by Yasuhiro Maeda Breakdown of academic impact, for papers by Yasuhiro Hashimoto Breakdown of academic impact, for papers by Biyin Cao Breakdown of academic impact, for papers by Tatiana Koudriakova Breakdown of academic impact, for papers by Anthony E. Boitano Breakdown of academic impact, for papers by David Meininger Breakdown of academic impact, for papers by Manuel Melo Pires Breakdown of academic impact, for papers by Kimiko Ishiguro
Rankless by CCL
2026